Human CD20 Antibody - Obinutuzumab IgG1 Isotype

Anti-CD20 antibody - Human IgG1 (high effector functions)

Anti-hCD20-Ga-hIgG1 is an Obinutuzumab-based research antibody with a human IgG1 constant region. Obinutuzumab is a type II (second generation) fully humanized, non-fucosylated IgG1 monoclonal antibody with improved therapeutic efficacy compared with previously developed type I (first generation) anti-hCD20 mAbs, such as Rituximab and Ofatumumab. Obinutuzumab (Afutuzumab, GA101) targets the human CD20 antigen found on the surface of normal and malignant B lymphocytes. Obinutuzumab has been approved by the FDA to treat chronic lymphocytic leukemia [1-3].

Anti-hCD20-Ga-hIgG1 features the variable region of Obinutuzumab and a human IgG1 constant region for high effector functions. For applications requiring even stronger Fc effector activity, InvivoGen also offers Anti-hCD20-Ga-hIgG1fut, the biosimilar research antibody to Obinutuzumab. 

Key features

• Each lot is functionally tested and validated
• The complete sequence of the antibody construct has been verified
• Absence of endotoxins determined by the EndotoxDetect™ assay

This antibody is suitable for effector function analysis, screening assays, and cytotoxic bio-assays. It can be used in ADCC effector activity assays in combination with Jurkat-Lucia™ NFAT-CD16 effector cells and Raji target cells.

InvivoGen also provides type I anti-hCD20 mAbs featuring the variable regions of Rituximab or Ofatumumab, with either native or engineered Fc region.

References:

1. Gagez AL. & Cartron G., 2014. Obinutuzumab: a new class of anti-CD20 monoclonal antibody. Curr Opin Oncol. 26(5):484-91.
2. Smolej L., 2014. Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab. Pharmgenomics Pers Med. 8:1-7.
3. Winiarska M. et al., 2011. Molecular mechanisms of the antitumor effects of anti-CD20 antibodies. Front Biosci (Landmark Ed). 16:277-306.